LEO Pharma Reports Positive Interim Data for Tralokinumab in Hand Eczema Trial

LEO Pharma announced encouraging 16-week interim results from the Phase IIIb ADHAND trial, evaluating tralokinumab (300mg biweekly) in adults with moderate-to-severe atopic dermatitis (AD) on the hands.

The trial met its primary endpoint, with more patients on tralokinumab achieving clear or almost clear skin scores (IGA-AHE 0/1) compared to placebo. Secondary endpoints showed significant reductions in itch and pain scores (≥4 points via HESD) and improvements in HECSI scores.

Tralokinumab, an IL-13 inhibitor, was well tolerated, with most side effects mild to moderate. The placebo-controlled, double-blind trial will continue through week 32, with final results expected later this year.

Following the interim phase, all participants will receive open-label tralokinumab every two weeks. These findings highlight potential benefits for treating difficult, high-burden areas like the hands.

10-07-2025